inclusion criteria: each subject must meet all of the following criteria to be entered into the randomized treatment in the study: 1. voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the informed consent form (icf); willingness and capability to complete all the study procedures 2. age 18-65 years (inclusive) at the time of signing icf 3. patients with laboratory confirmation of infection with sars-cov-2 by positive rapid antigen test for sars-cov-2 at screening. 4. recent onset (within 48 hours of time of consent) symptoms of mild covid-19 with oxygen saturation (spo2 \> 94 %) and respiratory rate \< 24 breaths/min. any of the covid-19 like symptoms including fever, cough, sore throat, malaise, headache, nasal congestion, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; (the maximum permitted difference in the time of onset of symptoms and the time of consent is 48 hours) 5. for female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test 6. eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barriermethods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. 7. not participating in any other interventional drug clinical studies before completion of the present study.

inclusion criteria: each subject must meet all of the following criteria to be entered into the randomized treatment in the study: 1. voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the informed consent form (icf); willingness and capability to complete all the study procedures 2. age 18-65 years (inclusive) at the time of signing icf 3. patients with laboratory confirmation of infection with sars-cov-2 by positive rapid antigen test for sars-cov-2 at screening. 4. recent onset (within 48 hours of time of consent) symptoms of mild covid-19 with oxygen saturation (spo2 \> 94 %) and respiratory rate \< 24 breaths/min. any of the covid-19 like symptoms including fever, cough, sore throat, malaise, headache, nasal congestion, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; (the maximum permitted difference in the time of onset of symptoms and the time of consent is 48 hours) 5. for female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test 6. eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barriermethods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. 7. not participating in any other interventional drug clinical studies before completion of the present study.

inclusion criteria: each subject must meet all of the following criteria to be entered into the randomized treatment in the study: voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the informed consent form (icf); willingness and capability to complete all the study procedures age 18-65 years (inclusive) at the time of signing icf patients with laboratory confirmation of infection with sars-cov-2 by positive rapid antigen test for sars-cov-2 at screening. recent onset (within 48 hours of time of consent) symptoms of mild covid-19 with oxygen saturation (spo2 > 94 %) and respiratory rate < 24 breaths/min. any of the covid-19 like symptoms including fever, cough, sore throat, malaise, headache, nasal congestion, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; (the maximum permitted difference in the time of onset of symptoms and the time of consent is 48 hours) for female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barriermethods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. not participating in any other interventional drug clinical studies before completion of the present study.

inclusion criteria: each subject must meet all of the following criteria to be entered into the randomized treatment in the study: voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the informed consent form (icf); willingness and capability to complete all the study procedures age 18-65 years (inclusive) at the time of signing icf patients with laboratory confirmation of infection with sars-cov-2 by positive rapid antigen test for sars-cov-2 at screening. recent onset (within 48 hours of time of consent) symptoms of mild covid-19 with oxygen saturation (spo2 > 94 %) and respiratory rate < 24 breaths/min. any of the covid-19 like symptoms including fever, cough, sore throat, malaise, headache, nasal congestion, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; (the maximum permitted difference in the time of onset of symptoms and the time of consent is 48 hours) for female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment urine pregnancy test eligible subjects of child-bearing age (female or male with female partner of childbearing age) must agree to take effective contraceptive measures (including hormonal contraception, barriermethods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. not participating in any other interventional drug clinical studies before completion of the present study.